Other languages Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
14.89 ^USD	+0.61%		+11.04%	+41.54%

May. 20	Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing	Mar. 07
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe	Feb. 22
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	Feb. 22
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01	Feb. 14
Sector Update: Health Care Stocks Rise in Afternoon Trading	Feb. 14
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment	Feb. 14
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-19
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22
Greenwich Lifesciences, Inc. Confirms the Interest in Both of Itsgp2 Phase Iib Clinical Trial and Phase Iii Clinical Trial, Flamingo-01	23-04-13
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15
Greenwich LifeSciences Launches Late-Stage Breast Cancer Trial	22-08-11
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial	22-08-11
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial	22-08-03
Greenwich LifeSciences to Offer Up to $100 Million in Common Shares Through Deal With Jefferies; Shares Jump	22-07-12
Greenwich LifeSciences Says FDA Removed Clinical Hold on Flamingo Phase 3 Clinical Trial	22-07-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Other languages

Filters